Preclinical toxicity of paclitaxel biopolymer formulationстатьяИсследовательская статья
Информация о цитировании статьи получена из
Web of Science,
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 10 февраля 2018 г.
Аннотация:2017, 17(15), 1661-1668
Abstract: Background: Poly(hydroxyalkanoates) (PHA) have recently attracted increasing attention due to their
biodegradability and high biocompatibility, which makes them suitable for the development of new prolong drug
formulations.
Objective: A preclinical toxicology study of paclitaxel biopolymer formulation (PBF) (paclitaxel-loaded poly(3-
hydroxybutyrate) (PHB) microparticles) was done in order to assess its safety and to forecast side and toxic effects
in a clinical study on patients.
Method: PHB microparticles loaded with antitumor cytostatic drug PTX were obtained by spray-drying method
using Nano Spray Dryer B-90. The comprehensive study of cytotoxicity (on bone marrow stem cells), acute and
chronic toxicity, allergenic and pyrogenic properties, histological investigation (in mice, rats and rabbits) of
obtained PBF was carried out.
Results: The acute toxicity study showed that PBF is much less toxic in equivalent PTX-content doses than PTX
in conventional formulation when administered intraperitoneally to mice and rats. However, the chronic toxicity
study showed that at intraperitoneal administration PBF has distinct cumulative properties and toxic effects that
prevent PBF from clinical testing in current composition.
Conclusion: Thus, the PBF as a prolong drug needs to correct its parameters for further drug formulation
development.